The Ubiquitin-specific Protease USP2a Enhances Tumor Progression by Targeting Cyclin A1 in Bladder Cancer

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2012 Feb 29

PMID 22370483

Citations 39

Authors

Jayoung Kim

Wun-Jae Kim

Zhiqian Liu

Massimo Loda

Michael R Freeman

Affiliations

Soon will be listed here.

Abstract

The deubiquitinating enzyme USP2a has shown oncogenic properties in many cancer types by impairing ubiquitination of FASN, MDM2, MDMX or Aurora A. Aberrant expression of USP2a has been linked to progression of human tumors, particularly prostate cancer. However, little is known about the role of USP2a or its mechanism of action in bladder cancer. Here, we provide evidence that USP2a is an oncoprotein in bladder cancer cells. Enforced expression of USP2a caused enhanced proliferation, invasion, migration and resistance to several chemotherapeutic reagents, while USP2a loss resulted in slower proliferation, greater chemosensitivity and reduced migratory/invasive capability compared with control cells. USP2a, but not a catalytically inactive mutant, enhanced proliferation in immortalized TRT-HU1 normal human bladder epithelial cells. USP2a bound to cyclin A1 and prevented cyclin A1 ubiquitination, leading to accumulation of cyclin A1 by a block in degradation. Enforced expression of wild type USP2a, but not an inactive USP2a mutant, resulted in cyclin A1 accumulation and increased cell proliferation. We conclude that USP2a impairs ubiquitination and stabilizes an important cell cycle regulator, cyclin A1, raising the possibility of USP2a targeting as a therapeutic strategy against bladder tumors in combination with chemotherapy.

Citing Articles

Roles of posttranslational modifications in lipid metabolism and cancer progression.

Feng T, Zhang H, Zhou Y, Zhu Y, Shi S, Li K Biomark Res. 2024; 12(1):141.

PMID: 39551780 PMC: 11571667. DOI: 10.1186/s40364-024-00681-y.

The role of deubiquitinase USP2 in driving bladder cancer progression by stabilizing EZH2 to epigenetically silence SOX1 expression.

Xu F, Xu X, Deng H, Yu Z, Huang J, Deng L Transl Oncol. 2024; 49:102104.

PMID: 39197387 PMC: 11399563. DOI: 10.1016/j.tranon.2024.102104.

Deubiquitylating Enzymes in Cancer and Immunity.

Ren J, Yu P, Liu S, Li R, Niu X, Chen Y Adv Sci (Weinh). 2023; 10(36):e2303807.

PMID: 37888853 PMC: 10754134. DOI: 10.1002/advs.202303807.

Targeting the deubiquitinase for malignant tumor therapy (Review).

Zhang S, Guo Y, Zhang S, Wang Z, Zhang Y, Zuo S Oncol Rep. 2023; 50(4).

PMID: 37594087 PMC: 10463009. DOI: 10.3892/or.2023.8613.

Dysregulation and oncogenic activities of ubiquitin specific peptidase 2a in the pathogenesis of hepatocellular carcinoma.

Zhang X, Nadolny C, Chen Q, Ali W, Hashmi S, Deng R Am J Cancer Res. 2023; 13(6):2392-2409.

PMID: 37424823 PMC: 10326592.

References

Black P, Dinney C . Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr Urol Rep. 2008; 9(1):55-61. DOI: 10.1007/s11934-008-0011-6. View

Wegiel B, Bjartell A, Ekberg J, Gadaleanu V, Brunhoff C, Persson J . A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer. Oncogene. 2005; 24(42):6385-93. DOI: 10.1038/sj.onc.1208795. View

Ma Y, Boucrot E, Villen J, Affar E, Gygi S, Gottlinger H . Targeting of AMSH to endosomes is required for epidermal growth factor receptor degradation. J Biol Chem. 2007; 282(13):9805-9812. DOI: 10.1074/jbc.M611635200. View

Fraizer G, Diaz M, Lee I, Grossman H, Sen S . Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol. 2004; 25(6):1631-9. View

Inuzuka H, Fukushima H, Shaik S, Liu P, Lau A, Wei W . Mcl-1 ubiquitination and destruction. Oncotarget. 2011; 2(3):239-44. PMC: 3260810. DOI: 10.18632/oncotarget.242. View

Kiemeney L, Witjes J, Verbeek A, Heijbroek R, Debruyne F . The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer. 1993; 67(4):806-12. PMC: 1968355. DOI: 10.1038/bjc.1993.147. View

Yang R, Morosetti R, Koeffler H . Characterization of a second human cyclin A that is highly expressed in testis and in several leukemic cell lines. Cancer Res. 1997; 57(5):913-20. View

Liou L . Urothelial cancer biomarkers for detection and surveillance. Urology. 2006; 67(3 Suppl 1):25-33. DOI: 10.1016/j.urology.2006.01.034. View

Liu D, Liao C, Wolgemuth D . A role for cyclin A1 in the activation of MPF and G2-M transition during meiosis of male germ cells in mice. Dev Biol. 2000; 224(2):388-400. DOI: 10.1006/dbio.2000.9776. View

10.

Muller-Tidow C, Wang W, Idos G, Diederichs S, Yang R, Readhead C . Cyclin A1 directly interacts with B-myb and cyclin A1/cdk2 phosphorylate B-myb at functionally important serine and threonine residues: tissue-specific regulation of B-myb function. Blood. 2001; 97(7):2091-7. DOI: 10.1182/blood.v97.7.2091. View

11.

Mirza A, Basso A, Black S, Malkowski M, Kwee L, Pachter J . RNA interference targeting of A1 receptor-overexpressing breast carcinoma cells leads to diminished rates of cell proliferation and induction of apoptosis. Cancer Biol Ther. 2005; 4(12):1355-60. DOI: 10.4161/cbt.4.12.2196. View

12.

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L . Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2006; 66(6 Suppl 1):4-34. DOI: 10.1016/j.urology.2005.07.062. View

13.

Sweeney C, Murphy M, Kubelka M, Ravnik S, HAWKINS C, Wolgemuth D . A distinct cyclin A is expressed in germ cells in the mouse. Development. 1996; 122(1):53-64. DOI: 10.1242/dev.122.1.53. View

14.

Liao C, Wang X, Wei H, Li S, Merghoub T, Pandolfi P . Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. Proc Natl Acad Sci U S A. 2001; 98(12):6853-8. PMC: 34442. DOI: 10.1073/pnas.121540098. View

15.

Allende-Vega N, Sparks A, Lane D, Saville M . MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene. 2009; 29(3):432-41. DOI: 10.1038/onc.2009.330. View

16.

Singhal S, Taylor M, Baker R . Deubiquitylating enzymes and disease. BMC Biochem. 2008; 9 Suppl 1:S3. PMC: 2582804. DOI: 10.1186/1471-2091-9-S1-S3. View

17.

Cognetti F, Ruggeri E, Felici A, Gallucci M, Muto G, Pollera C . Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol. 2011; 23(3):695-700. DOI: 10.1093/annonc/mdr354. View

18.

Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein L . The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell. 2004; 5(3):253-61. DOI: 10.1016/s1535-6108(04)00055-8. View

19.

Freeman M, Yoo J, Raab G, Soker S, Adam R, Schneck F . Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder. J Clin Invest. 1997; 99(5):1028-36. PMC: 507911. DOI: 10.1172/JCI119230. View

20.

Wolgemuth D . Function of the A-type cyclins during gametogenesis and early embryogenesis. Results Probl Cell Differ. 2011; 53:391-413. PMC: 4080912. DOI: 10.1007/978-3-642-19065-0_17. View